Insulet Corporation announced a voluntary Medical Device Correction for specific lots of its Omnipod products due to a manufacturing issue that could lead to insulin under-delivery. The company expects to incur up to $50 million in related costs in 2026 but does not anticipate an impact on its full-year guidance or product availability.
Key Details
- Event: A voluntary Medical Device Correction affecting approximately 7 million Omnipod Pods due to a manufacturing defect (cannula tears) that could cause insulin leaks.
- Financial Impact: The company anticipates up to $50 million in costs in 2026 related to the correction, which will be excluded from adjusted results. Its 2026 financial guidance remains unchanged.
- Operational Impact: Insulet has implemented corrective actions and does not expect any disruption to customer shipments or new customer starts. This action is separate from a previous correction announced on March 12, 2026.